Mindy Uhrlaub's Last Nerve: A Memoir of Illness and the Endurance of Family Launches Today (5/27/25)
One woman's story of confronting her genetic legacy and searching for a cure
AUSTIN, Texas, May 27, 2025--(BUSINESS WIRE)--Award-winning ALS activist and author Mindy Uhrlaub today launched her new book, Last Nerve: A Memoir of Illness and the Endurance of Family (River Grove Books). While caring for a sick mother, a son with behavioral problems, and a husband going through cancer treatments, Mindy discovered that she carries a gene for the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS). Last Nerve walks readers through how Mindy navigated the new territory of having three close relatives with life-threatening situations, and had to come to terms with the fact that she may have passed the fatal gene on to her two sons.
Not one to fold, Mindy faces her circumstances head-on, realizing that her race for the elusive cure for ALS is not only for herself but also for her kids, her cousins, and the thousands of other carriers of the fateful gene. Despite the incredible strain of all these challenges, Mindy manages them with amazing tenderness, persistence, and love. Far from a depressing story of misfortune, Last Nerve is as uplifting and witty as it is raw and real. It's a testament to hope, the endurance of family, and the resilience of the human spirit.
Early reviews for Last Nerve praise the book as a "heart-warming memoir of motherhood, ALS, and never backing down" (Publishers Weekly), and as a "complex and thoughtful remembrance about how family members can help one another through the worst of times" (Kirkus Reviews). Foreword also described Last Nerve as "uplifting in tone despite its grim subject matter, the book focuses on hope and resilience."
To learn more, please visit www.mindyuhrlaub.com or order Last Nerve at Amazon or Barnes & Noble.
Additional Praise for Last Nerve
"Mindy Uhrlaub's powerful and inspiring memoir is a work of courageous transformation. She deepens her soul by turning her pain into power and ardently committing herself to the struggle against ALS for the legacy of her mother, for herself, and for all those suffering from the disease. We are grateful."– V (FORMERLY EVE ENSLER), author of The Vagina Monologues and Reckoning
"The author's bulldog spirit summarizes it all. This beautifully written memoir shines light on her unrelenting courage and resilience to fight for societal and personal causes that are dear to her. It serves as a reminder for medical professionals to treat every individual with compassion and respect, because behind every individual seen in research or clinic lies a complex tapestry of arduous battles fought daily, unwavering love, and importantly, hope."– Suma Babu, MBBS, MPH, ALS neurologist at Massachusetts General Hospital
CONNECT WITH MINDY: Contact Bonnie Rice at Elevate Communications, brice@elevatecom.com
Interview: Schedule an interview with Mindy Uhrlaub about Last Nerve
Review: Reach out for a digital or hard copy of Last Nerve
Excerpt: If interested in publishing an excerpt from Last Nerve, indicate the chapter you would like to include
About Mindy UhrlaubMindy Uhrlaub is a founding member of End the Legacy. Her debut novel, Unnatural Resources, won the 2021 NYC Big Book Award for Cultural Heritage. Mindy also received the 2025 Harvey and Bonny Gaffen Advancements in ALS Award from the Les Turner ALS Foundation. She lives in Northern California with her family.
Follow Mindy at https://mindyuhrlaub.com, on X @MindyUhrlaub, and on Instagram @Mindywrites1.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527484654/en/
Contacts
Bonnie RiceElevate Communicationsbrice@elevatecom.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
RFK Jr. will ‘end the war' against alternative medicine at the FDA, from stem cell therapy to chelation. Here's what to know
Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health treatments during a recent podcast appearance, saying, 'We're going to end the war at the FDA against alternative medicine.' Speaking on the Ultimate Human podcast with host Gary Brecka, a 'renowned Human Biologist, biohacker, and longevity expert,' according to the website, Kennedy said he would fix the U.S. Food and Drug Administration's bias against the following: stem cell treatments, chelating drugs, vitamins and minerals, amino acids, peptides, and hyperbaric chambers. 'Our position is that the FDA has a job: Just do the science on these kinds of issues and then tell the public what they've learned from the science … but don't tell physicians what they can and cannot prescribe,' he said. And as far as the patients go, he said, 'If you want to take an experimental drug … you ought to be able to do that.' RFK Jr. added, 'We don't want to have the Wild West. We want to make sure that information is out there. But we also want to respect the intelligence of the American people' to decide what treatments will benefit them the most. He acknowledged that, with this approach, there will be 'charlatans' as well as 'people who have bad results' from various alternative treatments. 'But ultimately,' he said, 'you can't prevent that either way, and leaving the whole thing in the hands of pharma is not working for us.' Brecka called Kennedy's pronouncements 'music to my ears.' Below, what you need to know about the alternative therapies RFK Jr. is advocating for. What is it: It's a way to repair diseased or injured tissue in the body using stem cells—cells that can self-renew or become other types of tissues—typically grown in a lab, manipulated, and then be implanted into the patient. What it does: Though it's considered to be largely experimental, the FDA does permit stem cell therapies for blood and immune disorders. Leukemia, lymphoma, neuroblastoma, and multiple myeloma, for example, are also often treated this way, with bone marrow treatments, which are backed by decades of science. Other types of the treatment are still in clinical trials, while more and more wellness centers are offering the treatment for unapproved reasons, using cells drawn from the patient's body and injected back in without manipulation for everything from autism and ALS to Parkinson's and better skin, according to the New York Times. Kennedy told Brecka that he received the treatment for his voice disorder, spasmodic dysphonia, and that it helped him 'enormously,' but that he had to go to Antigua to access it. Risks: For starters, wellness clinic treatments cannot guarantee they are using actual stem cell, reported the Times. And improper injections can lead to a host of terrible consequences—clots, infections, blindness, and even the formation of tumors, which the FDA warned of in 2021. What it is: Chelation involves the use of certain chemicals to remove toxic heavy metals, such as mercury and lead, from the body; all FDA-approved chelation therapy products require a prescription and can only be used safely under the supervision of a healthcare practitioner. What it does: Some alternative medicine practitioners offer chelation therapy, through pill or injection, as a way to treat Alzheimer's, autism, diabetes, high blood pressure, or Parkinson's disease, all of which are unapproved and risky. Children's Health Defense, founded by Kennedy, has written about chelation as a way to treat autism, which compares 'autism with mercury poisoning' due to childhood vaccines that contained the preservative thimerosal (largely mercury) before it was removed in 2001. Some flu shots still contain the preservative, but, says the Centers for Disease Control and Prevention, 'There is no evidence of harm caused by the low doses of thimerosal in vaccines.' Risks: The FDA warns specifically about using chelation therapy for autism, and notes, 'Chelating important minerals needed by the body can lead to serious and life-threatening outcomes.' While minor risks may include fever, headache, muscle pain, and nausea or vomiting, severe reactions range from heart failure and kidney damage to respiratory failure and seizures, according to the Cleveland Clinic. What they are: Dietary supplements in almost every letter of the alphabet, from A to zinc, are over-the-counter pills or liquids that contain nutritional boosts of vitamins and minerals. What they aim to help: Vitamin and mineral supplements aim to fill in with necessary nutrients that a person is not getting through food—though nutritionists believe that healthy food is the best source of such vitamins and minerals. Studies have found supplements may help with practically any issue under the sun—energy, heart issues, cognitive function, gut health, sleep, and more. Risks: The U.S. Food and Drug Administration regulates supplements, but doesn't approve them for safety or effectiveness before they are sold to the public. Some may cause liver damage and toxicity, while others may just be a waste of money. What it is: Amino acids are often referred to as the 'building blocks of proteins,' needed for building proteins, hormones, and neurotransmitters. are compounds that play many critical roles in your body. You need them for vital processes such as building proteins, hormones, and neurotransmitters. Amino acids are concentrated in protein-rich foods such as meat, fish, and soybeans, and foods that contain all nine essential amino acids are called complete proteins. Peptides are short proteins, and come in the form of hormones such as follicle-stimulating hormone (FSH), and creatine and collagen. What they aim to help: Amino acid supplements may help with various issues—such as L-arginine for blood flow and inflammation; tryptophan for mood and sleep; and valine, leucine, and isoleucine to help with energy and athletic performance. Taking collagen supplements may help strengthen nails and bones, while people take creatine for boosting workouts and building muscle growth. Risks: Side effects of taking either can range from toxicity and gastrointestinal issues to effects on brain function muscle protein balance. Creatine may cause muscle cramps and digestive problems (and may not have many benefits), while tryptophan may cause dizziness, headache, or nausea. And again, as with all supplements, the U.S. Food and Drug Administration regulates them, but doesn't approve them for safety or effectiveness before they are sold to the public. What it is: Hyperbaric oxygen therapy in a medical-grade, FDA-approved chamber lets you breathe pure oxygen—as opposed to everyday air, which is just 21% oxygen mixed with nitrogen. Hyperbaric oxygen is also highly pressurized, thereby allowing the lungs to take more in. Home chambers (used by folks including Lebron James, LeAnn Rimes, and Mayim Bialik), as well as those offered in many wellness clinics, do not deliver 100% oxygen. Instead, they use regular air that is 30% more pressurized than normal for what's known as 'mild hyperbarics.' What it aims to help: The FDA has been regulating HBOT chambers since 1976, and has officially cleared 13 medical conditions—such as decompression sickness, burns, radiation injury, and certain wounds—for such treatment. But it's used off-label for many other reasons, including concussions, traumatic brain injury, long COVID, age reversal, stroke recovery, fibromyalgia, and improved brain function, many of which are being looked at in ongoing clinical trials. Risks: For medical-grade chambers, risks include ear and sinus pain, middle ear injuries, temporary vision changes, and lung collapse, which is rare, according to the FDA. For mild hyperbarics, risks include potential exposure to toxic oils from some compressors, carbon dioxide buildup that brings a risk of hypoxia inside the chamber—or, according to some experts and a body of inconclusive evidence, that the treatment may simply be ineffective. This story was originally featured on
Yahoo
13 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
